Share to: share facebook share twitter share wa share telegram print page

Jason S. Lewis

Jason S. Lewis
BornFebruary 1970
Liss, England
EducationBSc, University of Essex
PhD, University of Kent
Occupation(s)Radiochemist, professor
Scientific career
FieldsMolecular Imaging, radiochemistry
InstitutionsWashington University School of Medicine
Memorial Sloan Kettering Cancer Center

Jason S. Lewis is a British radiochemist whose work relates to oncologic therapy and diagnosis. His research focus is a molecular imaging-based program focused on radiopharmaceutical development as well as the study of multimodality (PET, CT & MRI) small- and biomolecule-based agents and their clinical translation.[1] He has worked on the development of small molecules as well as radiolabeled peptides and antibodies probing the overexpression of receptors and antigens on tumors.[2]

Education

Jason S. Lewis was born and raised in Horndean, Hampshire, England. Lewis received his Bachelor of Science in chemistry, B.Sc. from the University of Essex in 1992. He received his Master of Science in chemistry from the University of Essex in 1993.

In 1996, he received his Doctor of Philosophy in Biochemistry at the University of Kent.

Career

Lewis was an instructor of Radiology at the Washington University School of Medicine, Mallinckrodt Institute of Radiology from 2000 to 2002. From 2003 to 2008, he was an assistant professor of radiology at the Washington University School of Medicine, Mallinckrodt Institute of Radiology.[citation needed] He is the Emily Tow Jackson Chair in Oncology, the Vice Chairman for Research (Radiology) and Chief Attending of the Radiochemistry and Imaging Sciences Service at Memorial Sloan Kettering Cancer Center. He also heads a laboratory in the Sloan Kettering Institute's Molecular Pharmacology Program and is a professor at the Gerstner Sloan Kettering Graduate School of Biomedical Sciences.[3][4]

Lewis holds joint appointments in the Departments of Radiology and the Department of Pharmacology at Weill Cornell Medical School, NY.[citation needed]

Research focus

Lewis is a proponent of development imaging tools for use in personalized medicine. Lewis designs and develops radiochemical probes for use in nuclear medicine as well as multi-modality molecular imaging.[5] The use of these probes span from oncological metabolic detection to understanding the biological processes of cancer and pharmacological modification. These probes can be used for biomarkers in clinical trials as well as used as an agent for oncological diagnostics.[6][7] He has developed multiple new small molecules that target tumor metabolism, as well as radiolabeled peptides and antibodies for use in probing overexpression of receptors and antigens on tumors for research, clinical trials and in the clinic.[8]

Recognition

Editorial board memberships

References

  1. ^ "Professor Jason Lewis joins Clarity Pharmaceuticals' Advisory Board". Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging. 2018-10-11. Retrieved 2019-06-07.
  2. ^ Lewis, Jason S.; Evans, Michael J.; Fox, Ian L.; Caen, Jonathan D.; Dilling, Thomas R.; Dacek, Megan M.; Henry, Kelly E. (2019-01-01). "A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer". Clinical Cancer Research. 25 (1): 166–176. doi:10.1158/1078-0432.CCR-18-1485. ISSN 1078-0432. PMC 6320277. PMID 30228208.
  3. ^ "Jason S. Lewis". Memorial Sloan Kettering Cancer Center. Retrieved 2019-06-07.
  4. ^ "Our Faculty". Memorial Sloan Kettering Cancer Center. Retrieved 2019-06-17.
  5. ^ "The Jason Lewis Lab". Memorial Sloan Kettering Cancer Center. Retrieved 2019-06-07.
  6. ^ Lewis, Jason S.; Livingston, Philip O.; Scholz, Wolfgang W.; Sawada, Ritsuko; Ragupathi, Govind; Drobjnak, Marija; Sevak, Kuntal K.; Evans, Michael J.; Wu, Xiaohong (2013-11-01). "Applying PET to Broaden the Diagnostic Utility of the Clinically Validated CA19.9 Serum Biomarker for Oncology". Journal of Nuclear Medicine. 54 (11): 1876–1882. doi:10.2967/jnumed.113.119867. ISSN 0161-5505. PMC 4274751. PMID 24029655.
  7. ^ Viola-Villegas, Nerissa Therese; Carlin, Sean D.; Ackerstaff, Ellen; Sevak, Kuntal K.; Divilov, Vadim; Serganova, Inna; Kruchevsky, Natalia; Anderson, Michael; Blasberg, Ronald G. (2014-05-20). "Understanding the pharmacological properties of a metabolic PET tracer in prostate cancer". Proceedings of the National Academy of Sciences of the United States of America. 111 (20): 7254–7259. Bibcode:2014PNAS..111.7254V. doi:10.1073/pnas.1405240111. ISSN 1091-6490. PMC 4034234. PMID 24785505.
  8. ^ Lewis, Jason S.; Evans, Michael J.; Edwards, Kimberly J.; Abdel-Atti, Dalya; Dilling, Thomas R.; Henry, Kelly E. (2018-01-01). "Noninvasive 89Zr-Transferrin PET Shows Improved Tumor Targeting Compared with 18F-FDG PET in MYC-Overexpressing Human Triple-Negative Breast Cancer". Journal of Nuclear Medicine. 59 (1): 51–57. doi:10.2967/jnumed.117.192286. ISSN 0161-5505. PMC 5750524. PMID 28848040.
  9. ^ ACADAdmin (2017-01-08). "2014 Distinguished Investigators". The Academy for Radiology & Biomedical Imaging Research. Retrieved 2019-08-20.
  10. ^ "Fellows | World Molecular Imaging Society". www.wmis.org. Retrieved 2019-08-20.
  11. ^ "2017 Award Recipients - SNMMI". www.snmmi.org. Retrieved 2019-08-20.
  12. ^ "Jason Lewis Receives SNMMI Award - The ASCO Post". www.ascopost.com. Retrieved 2019-08-20.
  13. ^ "Society of Nuclear Medicine and Molecular Imaging Announces 2019 Fellows - SNMMI". www.snmmi.org. Retrieved 2019-08-20.
  14. ^ "Molecular Imaging and Biology - incl. option to publish open access (Editorial Board)". springer.com. Retrieved 2019-06-07.
  15. ^ "JNM -- The Journal of Nuclear Medicine Editorial Board". jnm.snmjournals.org. Archived from the original on 2019-05-28. Retrieved 2019-06-07.
  16. ^ Demoin, Dustin Wayne; Wyatt, Linden C.; Edwards, Kimberly J.; Abdel-Atti, Dalya; Sarparanta, Mirkka; Pourat, Jacob; Longo, Valerie A.; Carlin, Sean D.; Engelman, Donald M. (2016-09-21). "PET Imaging of Extracellular pH in Tumors with 64Cu- and 18F-Labeled pHLIP Peptides: A Structure–Activity Optimization Study". Bioconjugate Chemistry. 27 (9): 2014–2023. doi:10.1021/acs.bioconjchem.6b00306. ISSN 1043-1802. PMC 5034329. PMID 27396694.
  17. ^ Nuclear Medicine and Biology Editorial Board.
Kembali kehalaman sebelumnya